Pre-Seed3 March 2023

Presentient Technologies secures pre-seed funding from QVentures and Episode1 to develop clinical trial analytics software.

QVentures led the pre-seed round with backing from Episode1 and industry angels to support the Meristem platform.

£2.0MPre-Seed

Presentient Technologies develops software tools that provide predictive analytics and real-time monitoring for clinical trials.

Presentient Technologies has secured pre-seed funding in a round led by QVentures, with participation from Episode1 and industry angels. The capital will support the ongoing development of the company's Meristem software platform, which provides real-time analytics and predictive insights for pharmaceutical and drug development companies running clinical trials. Clinical trials often suffer from discrepancies between anticipated and actual treatment effects, leading to inflated costs and extended timelines. Presentient aims to address these inefficiencies by offering tools that project trial outcomes and flag safety concerns early.

From the founder

"Clinical trials are to medicine what elections are to democracy; they are the definitive process behind every significant step forwards and how we reason about what is effective and safe and what is not."

Tom Coates

Co-founder at Presentient Technologies

Investor perspective

"We are excited to be backing Dan and Tom in launching Presentient and its analytics platform, Meristem to market, making clinical trials both safer and more efficient. We’ve already seen their incredible impact during COVID-19 and QVentures believes their platform will save thousands of lives by accelerating traditional clinical trial approaches."

Harveer Bharaj

Principal, QVentures